SVB’s collapse is a reminder of how far IP finance still has to travel
Like many others, the bank held thousands of patents as security for loan deals, but almost certainly had no idea of their value – or lack of it
Like many others, the bank held thousands of patents as security for loan deals, but almost certainly had no idea of their value – or lack of it
Marconi's Kasim Alfalahi takes the top spot for Avanci's stellar showing in our countdown of the patent market’s most innovative and influential dealmakers and decision takers
We compiled data from Westfleet Advisors’ annual litigation funding reports to find patent finance shot up by nearly 50% since 2020 – to the benefit of rights holders
Royalties grow on the back of new deals and renewals; company also shares new details on legal fight with Oppo, which does not appear to have significantly dimmed income outlook
29 October 2021
New Crinetics spin-off is more evidence of the growing influence of models designed to monetise non-core life sciences assets
22 October 2021
Diagnostic innovation buyouts drive resurgence of med-tech deal-making
19 October 2021
Continued impact of Samsung deal pushes Swedish company’s royalty take near $300 million – but executives warn upcoming re-negotiations could produce temporary disruption again
19 October 2021
Transaction marks first outside patent acquisition since company was spun out from Huawei last year
13 October 2021
Saturday Opinion: A memorable two days in the Irish capital showed definitively that face-to-face trumps video and allowed for some detailed debate on key topics
09 October 2021
Merck has struck the biggest life sciences M&A deal of 2021 so far. Here are the four key IP-related takeaways.
07 October 2021
US federal court victory sets up the $13.4 billion drug for exclusivity until 2028
05 October 2021
Assignment records show that despite parent company’s vast backing for startups, Softbank Corp and its affiliates have not often come into the possession of significant third-party portfolios
04 October 2021
The Long Read: Companies in the life sciences sector have increasing options when seeking outside investment in IP enforcement campaigns, writes Michael Gulliford. But unique legal considerations and risk factors call for careful structuring of deals
29 September 2021
Unlock unlimited access to all IAM content